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Abstract
Objectives To investigate the value of local image variance
(LIV) as a new technique for quantification of hypointense
microvascular susceptibility-weighted imaging (SWI) struc-
tures at 7 Tesla for preoperative glioma characterization.
Methods Adult patients with neuroradiologically suspected
diffusely infiltrating gliomas were prospectively recruited
and 7 Tesla SWI was performed in addition to standard imag-
ing. After tumour segmentation, quantification of
intratumoural SWI hypointensities was conducted by the
SWI-LIV technique. Following surgery, the histopathological
tumour grade and isocitrate dehydrogenase 1 (IDH1)-R132H
mutational status was determined and SWI-LIV values were
compared between low-grade gliomas (LGG) and high-grade
gliomas (HGG), IDH1-R132H negative and positive tumours,
as well as gliomas with significant and non-significant con-
trast-enhancement (CE) on MRI.
Results In 30 patients, 9 LGG and 21 HGG were diagnosed.
The calculation of SWI-LIV values was feasible in all tumours.
Significantly highermean SWI-LIV values were found inHGG
compared to LGG (92.7 versus 30.8; p < 0.0001), IDH1-
R132H negative compared to IDH1-R132H positive gliomas
(109.9 versus 38.3; p < 0.0001) and tumours with significant CE
compared to non-significant CE (120.1 versus 39.0; p < 0.0001).
Conclusions Our data indicate that 7 Tesla SWI-LIV might
improve preoperative characterization of diffusely infiltrating
gliomas and thus optimize patient management by quantifica-
tion of hypointense microvascular structures.
Key Points
• 7 Tesla local image variance helps to quantify hypointense
susceptibility-weighted imaging structures.
• SWI-LIV is significantly increased in high-grade and IDH1-
R132H negative gliomas.
• SWI-LIV is a promising technique for improved preoperative
glioma characterization.
• Preoperative management of diffusely infiltrating gliomas
will be optimized.
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CSI Chemical shift imaging
DWI Diffusion weighted imaging
FWHM Full width at half maximum
GBM Glioblastoma multiforme
HGG High-grade gliomas
IDH1 Isocitrate dehydrogenase 1
LGG Low-grade gliomas
LIV Local image variance
MINC Medical imaging network common data
MPRAGE Magnetization prepared rapid gradient echo
NAWM Normal appearing white matter
nCBV Normalized cerebral blood volume
PET Positron emission tomography
RANO Response Assessment in Neuro-Oncology
rCBV Relative cerebral blood volume
ROI Region of interest
SD Standard deviation
SWI Susceptibility-weighted imaging
WHO World Health Organization
Introduction
Diffusely infiltrating gliomas are the most frequent primary
brain tumours in adults [1]. According to the current World
Health Organization (WHO) criteria, the histopathological
spectrum of diffusely infiltrating gliomas ranges from slowly
growing tumours (low-grade gliomas = LGG; WHO grade II)
to highly malignant neoplasms (high-grade gliomas = HGG;
WHO grades III and IV) [2]. Following neurosurgical resec-
tion or biopsy of HGG, immediate postoperative treatment
with radio- and/or chemotherapy is crucial, while in most
LGG maximal safe tumour resection without initial postoper-
ative therapy is performed [3–5]. LGG typically show malig-
nant progression to HGG within several years, where the for-
mation of pathological microvessels by neo-angiogenesis rep-
resents one of the key steps [2, 6]. Thus, the detection of these
pathological microvascular structures is crucial for histopath-
ological differentiation of LGG from HGG: while in LGG
(WHO grade II) angiogenic features are typically absent, glio-
blastoma multiforme (GBM; WHO grade IV), the most com-
mon and malignant form of glioma, is characterized by the
presence of pathognomonic microvascular proliferates [2, 6].
Nowadays, new molecular markers have been introduced
that are capable of further refining the classification of gliomas
into distinct subtypes [7, 8]. Most notably, presence of the
isocitrate dehydrogenase 1 (IDH1) mutation was shown to
be associated with WHO grade II/III gliomas and secondary
GBM as well as a significantly longer progression-free and
overall survival [7–10]. By far the most common IDH1 mu-
tation involves the amino acid 132 at exon 4 (IDH1-R132H)
[11]. More and more, molecular markers such as the IDH1
mutational status are increasingly incorporated in clinical
decision making in addition to the tumour grade. Furthermore,
it has been recently demonstrated that IDH1 mutant gliomas
particularly profit from aggressive tumour resections [12, 13].
Similarly to different microvascular patterns in gliomas of
various grades of malignancy, neo-angiogenesis, and thus for-
mation of pathological microvessels was found to be associ-
ated with IDH1/2 mutational status with increased neo-
angiogenesis in IDH1/2 wild-type gliomas and inhibition of
neo-angiogenesis in IDH1/2 mutant tumours [14]. Thus,
reliable identification of these pathological microvascular
structures is essential for preoperative glioma characterization
to plan the appropriate surgical strategy and postoperative
therapy, as well as assessment of the individual patient
prognosis.
Routinely, preoperative neuroradiological differentiation
between LGG and HGG is mainly based on the type of MRI
contrast-enhancement (CE) on T1-weighted images [15].
Pathological microvascular proliferation of HGG is associated
with impairment of the blood-brain barrier resulting in visible
leakage of contrast medium (CM) into the brain tumour tissue
on MRI [15]. Thus, the presence of significant CE is usually
considered as indicator of HGG, while LGG generally lack
unequivocal CE [2, 15, 16]. However, the type of CE on MRI
represents only an indirect sign of microvascular alterations.
Furthermore, assessment of gliomas by conventional contrast-
enhanced MRI is associated with specific drawbacks: (1)
Gliomas frequently show a diffuse pattern of CE that is not
able to differentiate specific structures such as the tumour
microvascularity [17, 18]. (2) Up to 50% ofHGG lack distinct
CE on MRI mainly due to insufficient extravasation of CM
that does not allow reliable visual detectability [19, 20].
(3) Additionally, in a fraction of patients the administration
of CM is not feasible due to CM specific contraindications
[21]. In recent years, also Badvanced imaging techniques^
are increasingly applied in addition to standard contrast-
enhanced MRI such as diffusion weighted imaging (DWI),
contrast and non-contrast perfusion MRI and MR spectros-
copy to optimize preoperative glioma grading [22, 23]. For
preoperative identification of the IDH1 mutational status,
reliable techniques are currently not available in routine
clinical practice so far although promising approaches such as
MR spectroscopy of 2-hydroxyglutarate were described [24].
Consequently, new reliable methods for direct visualization of
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pathological microvascularity in gliomasmust be developed for
preoperative estimation of the tumour grade and IDH1 muta-
tional status.
Susceptibility-weighted imaging (SWI) was reported so far
for different indications such as visualization of brain vascular-
ization, arteriovenous and cavernous malformations, multiple
sclerosis lesions, cerebral abscesses, stroke, brain function, and
brain tumours [17, 25–32]. Recently, it was found that SWI
hypointensities within gliomas are mostly caused by tumour
microvascularity, blood deposits, and calcifications that are fre-
quently observed in oligodendrogliomas and that application of
ultra high-field MRI using 7 Tesla SWI provides high spatial
resolution to visualize such pathological intratumoural alter-
ations [33–35]. To date, however, no reliable methods for pre-
cise quantification of these hypointense SWI structures have
been established in clinical routine. Here, we introduce the
SWI based local image variance (LIV) to quantify SWI
hypointensities. The LIV is a measure of image variation in
the vicinity of a pixel, which is in SWI increased in cases of a
high density of blood vessels or microbleeds represented as
signal loss on SWI images.
The aim of this study was thus to investigate the value of
LIV as a new technique for quantification of SWI
hypointensities at 7 Tesla for preoperative non-invasive assess-
ment of the tumour dignity in diffusely infiltrating gliomas.
Hence, we prospectively analyzed a series of adult glioma pa-
tients and compared 7 Tesla SWI-LIV values to the WHO




In this study, adult patients scheduled for neurosurgical
resection or biopsy of a radiologically suspected diffusely
infiltrating glioma (WHO grades II-IV) were prospectively
recruited between 2009 and 2015. This was a prospective,
single arm, non-randomized study. In each patient, 7 Tesla
MRI was performed prior to the neurosurgical procedure in
addition to standard imaging for calculation of SWI-LIV
values. None of the patients received previous surgery,
chemo- and/or radiotherapy for a brain tumour prior to
inclusion into this study. The protocol of this study was
approved by the local institutional review board and writ-
ten informed consent was obtained from all patients.
Patient characteristics are provided in Table 1.
Preoperative imaging
Routinely, preoperative MRI was performed on a 3 Tesla
scanner (Tim Trio, Siemens, Erlangen, Germany) in all pa-
tients as described previously [36, 37]. According to the type
of CE on MRI, we distinguished gliomas with significant
(ring-like or nodular) or non-significant CE (none, patchy/
faint or focal) [36–39]. In all patients with non-significant
CE, we performed an additional positron emission tomography
(PET) using amino acid tracer (11C-methionine or 18F-fluoro-
ethyl-L-tyrosine) and/or MRI spectroscopy, chemical shift
imaging (CSI), for detection of a potential metabolic
Bhotspot^ for tissue sampling [38, 39].
7 Tesla imaging
For the current study, we additionally performed a preopera-
tive 7 Tesla MRI (Magnetom©, Siemens Healthcare,
Erlangen, Germany) in all patients. In this study, only patients
were included in which a 24- or a 32-channel radio frequency
coil (Nova Medical, Wilmington, DE, USA) was applied in
the frame of the 7 Tesla MR investigations. All patients
underwent the same protocol for image acquisition including
a T1-weighted and a SWI sequence: (1) T1-weighted data
were acquired with and without CM administration
(Multihance; 0.2 mL per kilogram of body weight) using a
magnetization prepared rapid gradient echo (MPRAGE)
sequence with the following parameters: image-matrix =
320 × 320 pixels; resolution = 0.75 × 0.72 × 0.7 mm;
slices = 208; parallel imaging factor = 2, TR/TI/TE 3800/
1700/3.55 ms, acquisition time = 10:29 min. (2) Between
the T1-weighted measurements a SWI sequence with a TE
of 15 ms was performed to acquire SWI data (before CM
administration). Further sequence parameters were: TR =
28 ms; image-matrix = 704 × 704 pixels; slices = 96; paral-
lel imaging factor = 2, acquisition time = 10:18 min, reso-
lution = 0.3 × 0.3 × 1.2 mm. It is of note, that SWI was
acquired before CM administration. Phase filtering and
SWI image processing was performed directly by the
Siemens SWI sequence.
Definition of regions of interest
To define regions of interest (ROI), manual tumour segmen-
tation was performed using contrast-enhanced T1-weighted
sequences or T2-weighted/FLAIR images (3 Tesla MRI data)
and the StealthViz neurosurgical planning software (Version
1.2, Medtronic, Louisville, CO, USA). Referring to the
Response Assessment in Neuro-Oncology (RANO) criteria,
the extension of the glioma was defined by the contrast-
enhancing area on T1-weighted MR images in suspected
HGG with significant CE and by the non-enhancing hyperin-
tense lesion on T2-weighted/FLAIR sequences in suspected
LGG with no significant CE [40]. As LIV values describe the
image heterogeneity in neighbouring voxels, care was taken
not to include LIV values derived from heterogeneities caused
by other sources than pathological intratumoral alterations
such as the brain surface, neighbouring blood vessels or the
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ventricles. In such cases the initially segmented tumour ROI
was adjusted to exclude such confounding values.
SWI-LIV calculation
First of all, the segmented ROIs, the 3 Tesla T1-weighted as
well as the 7 Tesla T1-weighted and SWI data were converted
to the medical imaging network common data (MINC) format
(see also Supplementary Figure 1) [41]. The MINC format
and its corresponding toolbox were also used for image pro-
cessing. Before the LIV calculation, image pre-processing
was performed in which the SWI data were intensity-
corrected using histogram spline sharpening and afterwards
image intensity was rescaled in the arbitrary range between
Table 1 Patients’ characteristics
n %
number of patients 30 (100)
gender male : female 1 : 1.5
age (years) median (range) 51 years (21 - 78)









corpus callosum 1 (3)
MRI contrast - enhancement
significant ring-like 11 (36)
nodular 2 (7)
non-significant none 12 (40)
patchy/faint 3 (10)
focal 2 (7)
type of surgery resection 19 (64)
stereotactic biopsy 10 (33)
open biopsy 1 (3)
target for iOP tumour sampling




HGG glioblastoma (WHO grade IV) 12 (40)
gliosarcoma (WHO grade IV) 1 (3)
anaplastic astrocytoma (WHO grade III) 5 (18)
anaplastic oligodendroglioma (WHO grade III) 2 (7)
mixed oligoastocytoma (WHO grade III) 1 (3)
LGG oligodendroglioma (WHO grade II) 4 (13)
diffuse astrocytoma (WHO grade II) 4 (13)
mixed oligoastocytoma (WHO grade II) 1 (3)
IDH1 mutational status
IDH1-R132H negative tumour 15 (50)
IDH1-R132H positive tumour 15 (50)
CE contrast - enhancement; CSI chemical shift imaging; HGG high-grade gliomas; iOP intraoperative,
LGG low-grade gliomas, MR magnetic resonance imaging, PET positron emission tomography, WHO
World Health Organization; IDH1 isocitrate dehydrogenase 1
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0 and 100 [42]. These steps are crucial in order to avoid dif-
ferences in variance based on different image intensities. In
the next step, the 7 Tesla SWI-LIV was calculated by using a
modified version of the Steiner translation theorem [43]:
LIV ¼ G X 2 − G Xð Þ½ 2
where X is the pre-processed SWI image and G represents
Gaussian low pass filtering, where a kernel with a full width
at half maximum (FWHM) of 3 mm was found the most
appropriate for the current data.
Figure 1 illustrates the SWI-LIVon a simulated SWI image
including hypointense structures with varying density. To
quantify hypointensities (e.g. microvascularity) within patient
data, the segmented tumour ROIs were linearly transformed
from the 3 Tesla into the 7 Tesla image space using T1-
weighted images for registration. The mean SWI-LIV values
for the individual tumours were afterwards calculated using the
transformed tumour ROIs (see Figs. 3d, 4d, and 5d).
Neurosurgical procedures
During all glioma resections or biopsies a navigation system
(Stealth Station Cranial Mach 5 or S7; Medtronic, CO, USA)
with integrated T1-weighted contrast-enhanced MR images
was used. In gliomas with non-significant CE, additional
T2-weighted/FLAIR images and PET imaging or CSI were
co-registered with T1-weighted MRI. To avoid acquisition
of non-representative tumour tissue and thus histopathological
undergrading, we performed separate navigation-guided tis-
sue sampling from the area of unequivocal CE (gliomas with
significant CE) or the PET/CSI hotspot (gliomas with non-
significant CE) in all tumour resections or biopsies as previ-
ously described [37, 38, 44]. For intraoperative confirmation
of the correct tissue target area (CE, PET, or CSI) independent
of brain-shift, we additionally used 5-aminolevulinic acid
(5-ALA) during resections or biopsies as described previ-
ously in the vast majority of cases (n = 29 of 30 patients)
[36, 44].
Histopathology
Histopathological tumour diagnoses were made according to
the current edition of the WHO criteria [2]. The IDH1 muta-
tional status was analyzed by immunohistochemistry using
the IDH1-R132H mutation-specific antibody (anti-human
IDH1-R132H; pH6, 1:30, Dianova, Germany). The neuropa-
thologists were blinded to the MR-based SWI pattern of all
gliomas.
Glioma grading with standard MRI sequences
and SWI-LIV
To investigate the value of SWI-LIV for glioma grading, we
compared this technique for preoperative estimation of the
correct WHO grade (LGG versus HGG) with standard MR
sequences. For this purpose, an experienced neuroradiologist
graded all tumours in LGG and HGG using standard 3 Tesla
MR sequences (T1-weighted sequences with and without CM
and T2-weighted images). For comparison, all tumours were
additionally graded using the SWI-LIV values, where we ap-
plied a SWI-LIV cutoff value of 35 for differentiation of LGG
and HGG. This cut off value was defined prior to this analysis
by comparing SWI-LIV values between data sets of LGG and
HGG. Consequently, all tumours with SWI-LIV ≤ 35 were
classified as LGG and all gliomas with SWI-LIV > 35 as
HGG in this comparative analysis.
Statistical analysis
For statistical analyses, SPSS® version 23.0 software (SPSS
Inc., Chicago, IL, USA) was applied. We used a non-
Fig. 1 Illustration of the SWI - local image variance (LIV) calculation.
(A) The left image shows a simulation of blood vessels (hypointense
structures on a hyperintense background) as typically detected by SWI.
As illustrated in this image, the density of these simulated blood vessels
increases from the left to the right. Such an increasing density of blood
vessels is typically observed in high-grade gliomas. (B) The right image
illustrates the corresponding colour-coded SWI-LIV map, where LIV
values increase with the density of blood vessels. The LIV values reach
their maximum in the area with the highest density of the blood vessels.
Note, the simulated SWI image (left image) is a binary image and in-
cludes only the values 0 and 1, resulting in SWI-LIV values that are not
comparable to patient data
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parametric Mann-Whitney U test for comparison of SWI-LIV
with the WHO tumour grade, IDH1-R132H mutational status
and type of MRI CE. Furthermore, we applied the Spearman’s
rank correlation coefficient to analyze the correlation between
SWI-LIVand theWHO tumour grade. A p-value of <0.05 was
considered significant.
Results
Altogether 30 patients (18 women and 12 men) with a median
age of 51 years (range 21 to 78 years) were included. In 19
patients a tumour resection (64 %), 10 cases a stereotactic
biopsy (33 %), and one patient an open biopsy (3 %) was
performed. Histopathological WHO diagnosis revealed a
LGG in nine cases and a HGG in 21 patients. Further patient
characteristics are summarized in Table 1.
SWI-LIV and WHO tumour grade
Calculation of SWI-LIVmaps was feasible in all patients. The
mean SWI-LIV value of all gliomas was 74.1 with a standard
deviation (SD) of 56.2. We found a significantly higher mean
SWI-LIV in HGG (92.7; SD = 57.2) compared to LGG (30.8;
SD = 16.3; p < 0.0001) and a significant correlation of SWI-
LIV values with the WHO tumour grade (R = 0.81; p <
0.0001). See also Table 2, Figs. 2, 3, and 4.
SWI-LIV and IDH1-R132H mutational status
IDH1-R132H was not detected by immunohistochemistry in
15 gliomas (12 WHO grade IV and three WHO grade III
gliomas), while a positive IDH1-R132H status was observed
in the remaining 15 gliomas (nine WHO grade II, five WHO
grade III, and one WHO grade IV gliomas). The mean
SWI-LIV in IDH1-R132H negative gliomas (109.9; SD =
57.9) was significantly higher compared to IDH1-R132H pos-
itive gliomas (38.3; SD = 21.1; p < 0.0001). See also Table 2,
Figs. 2, 3, and 4.
SWI-LIV and type of contrast-enhancement
Significant CE on preoperative MRI was detected in 13 glio-
mas (11 ring-like and two nodular CE) and non-significant CE
was observed in 17 cases (12 none, three patchy/faint, and two
focal CE). We found significantly higher mean SWI-LIV
values in gliomas with significant CE (120.1; SD = 55.2) com-
pared to non-significant CE (39.0; SD = 20.4; p < 0.0001).
See also Table 2, Figs. 2, 3, and 4.
Comparison of glioma grading with standard MRI
sequences and SWI-LIV
According to standard 3 Tesla MR sequences, an experienced
neuroradiologist correctly graded six out of nine LGG and 14
out of 21 HGG. In contrast, SWI-LIV correctly graded six out
of nine LGG and 19 out of 21 HGG by using a SWI-LIV
cutoff value of 35. Therefore, the SWI-LIV value correctly
graded five more tumours (five HGG) than the neuroradiolo-
gist (see also Fig. 5).
Discussion
Herein, we describe a new technique for quantitative analysis
of hypointense SWI structures in diffusely infiltrating glio-
mas. In this prospective study using 7 Tesla MRI, we found
significantly higher SWI-LIV values in HGG compared to
LGG, IDH1-R132H negative compared to IDH1-R132H pos-
itive gliomas and tumours with significant CE compared to
non-significant CE on MRI.
SWI for visualization of tumour microvascularity
and current drawbacks
SWI is generally capable to visualize normal vascular brain
structures as well as pathological brain microvascularity and is
thus increasingly applied additionally to conventional MRI
[18, 33, 34]. Therefore, the use of SWI seems to be of special
value for characterization of tumour microvascularity to im-
prove preoperative glioma grading. In this sense, Li et al.
detected a significantly higher number of small vessels and
micro-haemorrhage volume in high-grade compared to low-
grade astrocytomas using 3 Tesla SWI [17]. Hori et al. ob-
served significantly higher SWI hypointensity ratios at 3 Tesla
MRI in HGG compared to LGG by semiquantitative assess-
ment [32]. Moreover, further studies using semiquantitative
Table 2 Correlation of SWI-LIV with the WHO tumour grade, IDH1




LGG 9 30.8 16.3 <0.0001
HGG 21 92.7 57.2
IDH1-R132H mutational status
positive 15 38.3 21.1 <0.0001
negative 15 109.9 57.9
CE on MRI
non-significant 17 39.0 20.4 <0.0001
significant 13 120.1 55.2
CE contrast enhancement, HGG high-grade gliomas, IDH1 isocitrate
dehydrogenase 1, LGG low-grade gliomas, MRI magnetic resonance
imaging, SD standard deviation, SWI susceptibility weighted imaging,
WHOWorld Health Organization
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analyses of 1.5 or 3 Tesla SWI data found a higher degree of
the Bintratumoral susceptibility signal intensity^ in HGG com-
pared to LGG [31, 45, 46]. Additionally, Moenninghoff et al.
observed an increasing tumour microvascularity in single
cases of high-grade compared to low-grade astrocytomas
using 7 Tesla SWI [47]. These authors also found that 7
Tesla MRI is capable to display the tumour microvascularity
more detailed compared to images derived from lower field
strengths [47]. In these studies, different methods have
been applied for analysis of intratumoral SWI hypointensities
that are, however, mainly based on visual and semiquan-
titative assessment and are thus subjective and observer
dependent. So far, no reliable methods for precise quanti-
fication of hypointense SWI structures have been
established in clinical routine. Consequently, the development
of clinically reliable techniques for precise quantification of
intratumoral SWI hypointensities that are more objective is of
major importance.
Present study: SWI-LIV and WHO tumour grade
We introduce herein a new technique for quantification of
SWI hypointensities by using the so-called local image
variance. In this study, SWI was performed on 7 Tesla with
the advantage of a higher contrast and resolution for im-
proved visualization of tumour microvascularity compared
to lower field strengths. By clinical application of this tech-
nique, we found a significantly higher mean SWI-LIV in
HGG compared to LGG and observed a strong correlation
of SWI-LIV with the tumour grade. Compared to semi-
quantitative parameters, the SWI-LIV technique allows a
precise quantitative analysis of SWI hypointensities that
correspond mainly to tumour microvascularity and
microhemorrhages. Thus, the SWI-LIV technique represents a
new clinically reliable and objective technique for improved
preoperative glioma grading. Consequently, clinical application
of SWI-LIV will in future improve planning of the appropriate
postoperative therapy and assessment of individual patient
prognosis.
SWI-LIV and IDH1 mutational status
The preoperative knowledge of the IDH1 status is of major
interest for further patient management/surgical strategy since
it was shown in a recent study that the IDH1 mutational status
has a crucial impact on the surgical benefit: While patients
with IDH1 wild-type malignant gliomas do not profit from
further removal of the non-enhancing tumour in addition to
the enhancing tumour, this surgical strategy results in a signif-
icantly prolonged overall survival in patients with IDH1mutant
tumours [12, 13]. Interestingly, we observed a significantly
higher mean SWI-LIV in IDH1-R132H negative compared to
IDH1-R132H positive gliomas. Therefore, the SWI-LIV tech-
nique might in future also preoperatively identify candidates
that particularly profit from aggressive glioma resections. To
our knowledge, this is the first systematic analysis of SWI in
the subgroup of IDH1-R132H negative and positive diffusely
infiltrating gliomas. This is in accordancewith a recent study by
Kickingereder et al. that reported a markedly higher relative
cerebral blood volume (rCBV) in IDH1/2 wild-type gliomas
compared to IDH1/2 mutant gliomas [14]. Similarly, Lee et
al. found that IDH1 negative gliomas were characterized by
higher 90th percentile normalized cerebral blood volume
(nCBV) values as well as a steeper slope in histograms includ-
ing cumulative nCBV data [48]. Accordingly, Yamashita et al.
observed a significantly increased absolute tumour blood flow
measured by arterial spin-labelling/perfusion-MRI and tumour
necrotic area on MRI in IDH1 wild-type compared to IDH1
Fig. 2 Boxplot diagrams for comparison of SWI-LIV values with tu-
mour grade, IDH1-R132H mutational status and type of CE on MRI.
(A) SWI-LIV and tumour grade: The mean SWI-LIV was significantly
higher in HGG as compared to LGG (92.7 versus 30.8; p < 0.0001). (B)
SWI-LIV and IDH1-R132H mutational status: The mean SWI-LIV was
significantly higher in IDH1-R132H negative gliomas as compared to
IDH1-R132H positive gliomas (109.9 versus 38.3; p < 0.0001). (C)
SWI-LIV and type of CE on MRI: The mean SWI-LIV was
significantly higher in gliomas with significant CE as compared to
non-significant CE (120.1 versus 39.0; p < 0.0001)
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mutant GBM [49]. These data including our own findings
demonstrate that assessment of SWI and perfusion values
is a promising method not only for preoperative determination
of the correct WHO tumour grade, but also the IDH1mutation-
al status in gliomas. However, our initial observation should be
confirmed also in future studies and SWI values should be
correlated with perfusion parameters. One current shortcoming
is that SWI-LIV values can be increased in case of a HGG or an
IDH1-R132H negative glioma and thus the SWI-LIV technique
alone cannot differentiate between these two aspects. To over-
come this limitation, the combination of SWI-LIV with other
imaging sequences such as MR spectroscopy might be consid-
ered in future to distinguish between IDH1-R132H positive and
negative gliomas independent of the WHO tumour grade.
SWI-LIV and CE on MRI
Finally, we observed significantly higher mean SWI-LIV
values in gliomas with significant CE compared to non-
significant CE on preoperative MRI. Consequently, the appli-
cation of SWI might be of special value in patients with con-
traindications to CM administration such as severe renal in-
sufficiency [21]. Furthermore, SWI represents a powerful
method for visualization of the internal architecture of brain
tumours such as the tumour microvascularity that provides
complementary information to conventional MRI [17, 18,
50]. In this sense, SWI-LIV maps might identify also areas
of increased tumour microvascularity corresponding to early
malignant transformation of initially LGG prior to the




MR images and (B) contrast-
enhanced T1-weighted sequences
show a hyperintense lesion in the
posterior portion of the corpus
callosum with significant (ring-
like) CE. (C) 7 Tesla SWI detects
markedly increased intratumoral
hypointense structures. (D) The 7
Tesla SWI is overlaid with the
corresponding SWI-LIV map.
The colour-coded SWI-LIV map
in this glioma shows high values
(mean SWI-LIV: 135.7) for areas
with a high variability that
correspond probably to
intratumoral regions with high
amounts of pathological
microvessels and
microhaemorrhages. It is of note
that the area, where LIV values
are shown, represents the
segmented tumour ROI. (E)
Histopathological examination
reveals a HGG (GBM; WHO
grade IV) with (F) negative
IDH1-R132H mutational status.
Original magnification of the
H&E stain (E) and IDH1-R132H
stain (F) is × 200
Eur Radiol (2017) 27:1556–1567 1563
presence of significant CE on MRI in selected cases (see
Fig. 5). Interestingly, five HGG of this study were only de-
tected by the SWI-LIV technique, but not by an experienced
neuroradiologist analyzing standard MR sequences including
contrast-enhanced images.
Specific characteristics of the SWI-LIV technique
In order to calculate robust and comparable SWI-LIV maps, it
is crucial to acquire all SWI images with the same imaging
parameters. Additionally, image pre-processing is important
to remove low-frequency intensity gradients, which are com-
mon in ultra high-field images. Also, initial image intensities
can differ between MRI measurements. Consequently, correc-
tion of intensity difference is essential to avoid a LIV offset.
As we used two different coils (24- and 32-channel coils) for 7
Tesla MRI, we evaluated SWI-LIV values in normal
appearing white matter (NAWM) regions at the level of the
lateral ventricles in all data sets and found no significant dif-
ference in these ROIs between the two different coils.
Therefore, both coils can be applied for the calculation of
SWI-LIV values at 7 Tesla MRI according to our experience.
Although our SWI-LIV maps were based on 7 Tesla data, the
SWI-LIV technique is by no means limited to 7 Tesla. To
demonstrate the feasibility of the SWI-LIV technique also in
MR investigations with lower field strengths, we performed a
SWI-LIV analysis in two representative patients (one LGG
and one HGG) of our study in which 3 Tesla SWI data sets
were available. According to this analysis, we found that the
calculation of SWI-LIV is in principle also feasible in MR
Fig. 4 Representative case of a
LGG with positive IDH1-R132H
mutational status. (A)
Preoperative axial T2-weighted
MR images and (B) contrast-
enhanced T1-weighted sequences
demonstrate a left frontal
hyperintense lesion with non-
significant (patchy/faint) CE. (C)
7 Tesla SWI detects only very few
hypointense structures and (D)
the corresponding colour-coded
SWI-LIV map shows low values
in the tumour ROI (mean SWI-
LIV: 32.2). (E) Histopathological
examination reveals a LGG (dif-
fuse astrocytoma WHO grade II)
with (F) positive IDH1-R132H
mutational status. Original mag-
nification of the H&E stain (E)
and IDH1-R132H stain (F)
is × 200
1564 Eur Radiol (2017) 27:1556–1567
investigations with lower field strengths. However, the value
of the SWI-LIV technique for analysis of data derived from
scanners with lower field strengths that are more widely avail-
able should be investigated in future. Another future step
should be the introduction of a cutoff value in order to auto-
matically classify tumours as either LGG or HGG. With a
SWI-LIV cutoff value of 35, we were able to estimate the
correct glioma grade (LGG versus HGG) more frequently
with the SWI-LIV technique compared to the judgment of
an experienced neuroradiologist using standard MR se-
quences. However, the SWI-LIV cutoff value is largely de-
pendent on the imaging parameters as well as the whole image
processing pipeline and thus needs to be validated on a larger
number of data sets and hardware configurations. Finally,
since SWI data were acquired before administration of the
CM, we cannot provide data in this study concerning the po-
tential effect/influence of CM on SWI data.
Conclusions
Our data indicate that 7 Tesla SWI-LIV is a promising method
for quantification of SWI hypointensities in diffusely infiltrat-
ing gliomas. Significant differences in SWI-LIV values were
found dependent on the WHO tumour grade, IDH1-R132H
mutational status and type of MRI contrast-enhancement.
Consequently, the clinical use of SWI-LIV might in future
improve the preoperative glioma characterization and will
thus optimize the patient management.
Fig. 5 Preoperative identification
of early malignant transformation
in an initially suspected LGG on
conventional MRI. (A)
Preoperative axial T2-weighted
MR images and (B) contrast-
enhanced T1-weighted sequences
reveal a left frontal hyperintense
lesion with non-significant (none)
CE. (C) Although no CE is visible
on conventional MRI, 7 Tesla
SWI depicts markedly increased
intratumoural hypointense
structures and (D) the
corresponding colour-coded
SWI-LIV map shows high values
in the tumour ROI (mean SWI-
LIV: 82.0). (E) Histopathological
examination depicts already a
HGG (anaplastic
oligodendroglioma WHO grade
III) with a (F) markedly increased
proliferation rate (MIB-1
labelling index: 30 %). Original
magnification of the H&E stain
(E) and anti–Ki 67 stain (F)
is × 200
Eur Radiol (2017) 27:1556–1567 1565
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